Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Name: Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
License: Public Domain

Sanofi

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

type 2 diabetes mellitus

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 356639
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.